Inogen Appoints Experienced Medical Device Executive Andy Reding as Chief Operating Officer
INGN sits 25% above its 52-week low of $5.34.
Summary
Inogen appointed Andrew Reding as Chief Operating Officer, a strategic move to enhance operational performance and drive revenue, supported by a significant equity grant.
Key Events · Executive and Board Changes · INGN
-
New Chief Operating Officer Appointed
Andrew Reding, an experienced medical device executive, will join as Executive Vice President, Chief Operating Officer, effective July 6, 2026.
-
Strategic Focus on Operations
Mr. Reding will be responsible for driving revenue, operational performance, and aligning cross-functional priorities to execute Inogen's strategy.
-
Significant Equity Grant
The new COO will receive 130,000 restricted stock units (RSUs), valued at approximately $871,000, vesting one-third annually over three years as an inducement award.
-
Compensation Package Details
The compensation includes an annual base salary of $500,000, a target annual bonus opportunity of 70% of base salary, and a $100,000 cash sign-on bonus.
Analysis · INGN · Industrial Applications And Services
Inogen has appointed Andrew Reding, an executive with over 30 years of experience in medical technology, as its new Chief Operating Officer. This strategic hire aims to strengthen leadership, drive revenue, and improve operational performance, which is critical given the company's recent report of a wider GAAP net loss and negative Adjusted EBITDA. The compensation package includes a substantial equity award of 130,000 restricted stock units, valued at approximately $871,000 based on the current stock price, representing a significant incentive for the new COO.
At the time of this filing, INGN was trading at $6.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $180M. The 52-week trading range was $5.34 to $9.13. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.